World-class cells made available at scale

High quality MSCs from the facility in Stockholm

We offer allogeneic bone-marrow derived mesenchymal stromal cells (MSC) for preclinical applications, and plan to offer a GMP version for clinical applications. The cell production is based on 20 years of research and clinical experience from Karolinska Institutet, and our large scale facility allows for high quality at competitive prices. The cells are delivered according to your needs and can be quickly thawed and administered.

Research grade Mesenchymal stromal cells

  • 1 or 10 million cells per vial
  • Bone marrow from young and healthy volunteers
  • Xeno-free
  • Passage 2
  • International delivery in dry ice

Price per million cells:
  • 1-4M cells: €650
  • 5M+ cells: Please contact us
  • 10M+ cells: Please contact us

Order

GMP Mesenchymal stromal cells

  • Adjustable amount and vial size per dose
  • Bone marrow from young and healthy volunteers
  • Xeno-free
  • Different packaging depending on your needs
  • International delivery in liquid nitrogen


Please contact us for more information and how we can best suit your needs .




Contact


Product Information


FAQ

What is the source of your cells?

Do you offer MSCs at different passages?

Why are your MSCs better than other MSCs?

How is the morphology of your hBM-MSCs?

How do you characterize your hBM-MSCs?
What diseases are your donors screened for?

What does Xeno-free mean?

How to expand your hBM-MSCs?

Are cells from a single or pool of donors in each vial?

Do you recommend surface treatment before culturing?

Selected publications by our scientists

Boberg, E., von Bahr, L., ... K., Kadri, N., & Le Blanc, K. (2020). Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study. Stem cells translational medicine9 (10), 1190–1202. https://doi.org/10.1002/sctm.20-0099

Simonson, OE, … Le Blanc, K. (2015). In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. Stem cells translational medicine4 (10), 1199–1213. https://doi.org/10.5966/sctm.2015-0021

von Bahr, L., ... Le Blanc, K. (2012). Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem cells (Dayton, Ohio)30 (7), 1575–1578. https://doi.org/10.1002/stem.1118

Krampera, M., & Le Blanc, K. (2021). Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell stem cell28 (10), 1708–1725. https://doi.org/10.1016/j.stem.2021.09.006


Looking for treatments?

Cellcolabs does not provide treatments directly. However, we can provide updates on how and when it is possible to join the clinical studies that we sponsor or partner with in coming years.

Sign up for our newsletter